Fluasterone

Fluasterone is a potent G6PD inhibitor with a Ki of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active[1][2][3].

Product Specifications

CAS Number

[112859-71-9]

UNSPSC

12352211

Target

Mitochondrial Metabolism

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/fluasterone.html

Purity

99.85

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@](C[C@@H](F)C2=O)([H])[C@@]3([H])[C@]([C@@]4(C(CCCC4)=CC3)C)([H])CC1

Molecular Formula

C19H27FO

Molecular Weight

290.42

References & Citations

[1]Schwartz AG, et al. Potential therapeutic use of dehydroepiandrosterone and structural analogs. Diabetes Technol Ther. 2001 Summer;3 (2) :221-4.|[2]Pashko LL, et al. Antihyperglycemic effect of dehydroepiandrosterone analogue 16 alpha-fluoro-5-androsten-17-one in diabetic mice. Diabetes. 1993 Aug;42 (8) :1105-8.|[3]Schwartz AG, et al. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16alpha-fluoro-5-androsten-17-one and its reversal by NADPH liposomes. Cancer Lett. 2001 Jul 10;168 (1) :7-14.|[4]Schwartz AG, et al. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16alpha-fluoro-5-androsten-17-one and its reversal by NADPH liposomes. Cancer Lett. 2001 Jul 10;168 (1) :7-14.